CMUH upholds its professional role and mission as a medical institution. In response to global trends and emerging technologies, we are actively developing frontier medicine, including stem cell therapy, immune cell therapy, gene therapy, and other innovative medical technologies. We are also actively working on big data, precision medicine, AI vaccine R&D, artificial intelligence in medicine, and fostering academia-industry collaboration to create spin-off businesses. For example, Ever Supreme Bio-Technology Co offers technology platforms for stem cells and immune cells. Ever Fortune AI Co focuses on digital healthcare services. Ever Young BioDimension Corp is developing multi-dimensional printing and precision medicine.
Through developing cutting-edge and digital healthcare and integrating academic, medical,and industrial R&D synergies, the hospital hopes to improve its global competitiveness, build an ecological chain for the biomedical industry, protect human health, fulfill corporate social responsibility,and create corporate social responsibility new values for prosperity and sharing.
Innovation Technology Transfer/11 spin-off companies
EverFortune.AI is committed to innovative developments in artificial intelligence, smart medicine, and precision medicine as a pioneer of digital healthcare. Since its establishment, the company has won three world-class silver medals in AI contests and National Innovation Award for three consecutive years. In addition, the company has received 12 FDA approvals from Taiwan and the US,along with 17 patents. Recently, the team has strived to meet international standards while expanding its partnerships worldwide.
Ever Supreme Bio-Technology Co.
Founded in 2017, Ever Supreme Bio-Technology Co. is dedicated to the development of two core technology platforms for immune cells and stem cells, with a focus on new drug R&D and cellular contract manufacturing (Regulations Governing the Application or Use of Specific Medical Techniques or Examinations, or Medical Devices) to provide a wide range of cellular therapy products and offer more treatment options to doctors and patients.
In terms of new drug development, several new allogeneic cellular drugs will be submitted for clinical trials.
- UMSC01 for AMI is expected to apply for Phase II clinical trials in 2022.
- UMSC01 for multiple sclerosis (MS) is expected to apply for US FDA Phase I/IIa this year.
- Car001 (car-t) has been submitted to the US FDA for Pre-IND meeting in Q4 2021 and is expected to apply for the clinical trial I/IIa in 2022.
- Regarding allogeneic gamma-delta T for the treatment of solid cancer indications, CDE has been consulted to apply for the Phase I/II new drug clinical trial in aGDT in 2022.
Ever Young BioDimension Co.
Ever Young BioDimension is a CMU spin-off enterprise dedicated to being a frontier precision healthcare tech and service company in Asia-Pacific.We provide the advanced digital medical solution,innovative biomaterials, and personalized medical devices for surgery. Ever Young owned ISO 13485 and GMP certifications, 6 TFDA approval medical devices, and 5 innovative patents.